Laraway Financial Advisors Inc Sells 114 Shares of Eli Lilly and Company $LLY

Laraway Financial Advisors Inc decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.1% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,680 shares of the company’s stock after selling 114 shares during the period. Eli Lilly and Company accounts for about 1.6% of Laraway Financial Advisors Inc’s portfolio, making the stock its 17th biggest position. Laraway Financial Advisors Inc’s holdings in Eli Lilly and Company were worth $2,089,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Roundview Capital LLC lifted its holdings in Eli Lilly and Company by 19.8% in the second quarter. Roundview Capital LLC now owns 5,650 shares of the company’s stock valued at $4,404,000 after buying an additional 933 shares during the period. Sachetta LLC raised its position in shares of Eli Lilly and Company by 12.6% during the 2nd quarter. Sachetta LLC now owns 188 shares of the company’s stock valued at $146,000 after acquiring an additional 21 shares during the last quarter. Sunbeam Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 27.6% in the 2nd quarter. Sunbeam Capital Management LLC now owns 2,328 shares of the company’s stock valued at $1,814,000 after purchasing an additional 503 shares during the period. KLP Kapitalforvaltning AS lifted its stake in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 304,019 shares of the company’s stock valued at $236,992,000 after purchasing an additional 10,000 shares during the period. Finally, Spear Holdings RSC Ltd bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth $41,471,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $845.40 on Tuesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company’s 50 day moving average price is $735.35 and its two-hundred day moving average price is $765.48. The company has a market capitalization of $800.14 billion, a P/E ratio of 55.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 earnings per share. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. Cantor Fitzgerald cut their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $938.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.